Compare Hims and Hers Health Inc (HIMS) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs Thomson Reuters Corp — how do they compare? Hims and Hers Health Inc trades at $32.42 (market cap $7.57B), while Thomson Reuters Corp trades at $91.5 (market cap $41.28B). The key difference: Thomson Reuters Corp is far larger — about 5.5× Hims and Hers Health Inc's market cap, and Thomson Reuters Corp pays a 2.75% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals.
| HIMS | TRI | |
|---|---|---|
Market Cap | $7.57B | $41.28B |
Sector | Health | Industrials |
52-Week High | $66.18 | $205.54 |
52-Week Low | $14.52 | $76.55 |
Enterprise Value | $7.95B | $43.24B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health trades at $32.70, down 0.43% on the day, with a bearish technical signal despite bullish moving averages. The company reported $2.35 billion in 2025 revenue but swung to a projected net loss for 2026, with mixed quarterly earnings results. Recent news highlights executive changes and anticipation for Q2 2026 results on August 10, 2026, with analyst sentiment leaning toward a Buy consensus.
The outlook is cautious due to profitability concerns and high valuation multiples, but growth opportunities in weight-loss and telehealth services offer potential. Key risks include execution challenges and regulatory scrutiny. The stock presents a speculative growth play with a consensus price target of $33.57, slightly above the current price.
Thomson Reuters (TRI) trades at $95.43, down 0.8% today, with a bullish technical signal and strong analyst consensus. The stock shows robust profitability with a 19.93% net margin and has beaten earnings estimates in two of the last three quarters. Recent corporate actions include a special dividend and a reverse stock split, while news highlights AI integration and a joint venture with KKR.
Outlook is positive with a consensus price target of $129.96 implying 36% upside, supported by solid cash flow and debt reduction. Risks include execution of AI strategy and competitive pressures. Wall Street sentiment is bullish with 52% buy ratings, but investors should monitor Q2 2026 earnings due August 5 for confirmation of growth trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
